Drug Trial Radar · NCT05054387
China Post-marketing Surveillance (PMS) Study of Fabrazyme®
Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Oct 13, 2021
Primary completion
Mar 9, 2023
Study completion Mar 9, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with Fabry Disease.
Conditions
- Fabry Disease
Interventions
Agalsidase betaDrug
Powder for concentration into a solution Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (AEs)Time frame: Baseline to week 50
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number :1560003
Beijing, China
Investigational Site Number :1560002
Beijing, China
Investigational Site Number :1560001
Shanghai, China
Investigational Site Number :1560004
Shanghai, China
Investigational Site Number :1560006
Taiyuan, China
Investigational Site Number :1560005
Wuhan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.